Grants per year
Grants
Search results
-
Active
Prot#RNHE2041: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)
TMC Pharma Services Ltd., Salix Pharmaceuticals, Inc.
9/17/18 → 9/17/22
Project: Research project
-
A Multi-Center Group to Study Acute Liver Failure
University of Texas Southwestern Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases
9/16/15 → 8/31/21
Project: Research project
-
Prot# 017-00: A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial
Merck Sharp & Dohme Corporation
3/18/13 → 3/31/21
Project: Research project
-
Finished
Frailty and Functional Status in Older Liver Transplant Patients
University of California, San Francisco, National Institute on Aging
9/15/18 → 8/31/19
Project: Research project
-
A Phase 2a Study to Evaluate the Safety and Tolerability of OCR-002 (ornithine phenylacetate) in the Treatment of Patients with Acute Liver Failure/Severe Acute Liver Injury (STOP-ALF) -- A Multi-Center Group to Study Acute Liver Failure
University of Texas Southwestern Medical School, National Institute of Diabetes and Digestive and Kidney Diseases
9/18/15 → 8/31/19
Project: Research project
-
Prot #MK-3682-012-01: A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT3 Infection.
Merck Sharp & Dohme Corporation
8/5/15 → 8/5/18
Project: Research project
-
Prot # ROF-NASH_205: A Randomized, Double-Blind, Controlled, Multi-Center Phase 2 Study to Evaluate the Effect of Roflumilast Plus Pioglitazone on Liver Enzymes and Liver Fat Content in Subjects with Nonalcoholic Steatohepatitis
Ganger, D. R., Green, R., Kulik, L. M. & Rinella, M. E.
Quintiles, Inc., Takeda Development Center Americas, Inc.
2/11/14 → 2/11/17
Project: Research project
-
RFHE4043: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Rifaximin 550 mg in Subjects with Severe Hepatic Impairment and Overt Hepatic Encephalopathy
Valeant Pharmaceuticals North America LLC, Salix Pharmaceuticals, Inc.
3/12/13 → 12/31/15
Project: Research project
-
Protocol # 038-00: A Phase II Randomized, Dose Ranging, Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Doses of MK-5172 when Administered Concomitantly with Peginterferon alfa-2b and Rabavirin in Treatment Naive Subjects wi
Merck Sharp & Dohme Corporation
1/24/13 → 1/24/16
Project: Research project
-
Prot # GS-US-337-0109: A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination ± Ribavirin for 12 and 24 Weeks in Treatment-Experienced Subjects with Chronic Genotype 1 HCV I
PRA Health Sciences, Gilead Sciences, Inc.
1/4/13 → 1/4/17
Project: Research project
-
Prot # GS-US-337-0102: A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed Dose Combination ± Ribavarin for 12 and 24 Weeks in Treatment-Naive Subjects with Chronic Genotype 1 HCV Infecti
PRA Health Sciences, Gilead Sciences, Inc.
10/5/12 → 10/5/15
Project: Research project
-
Prot # 003-23: A Phase II Randomized, Partially Blinded, Pilot Study to Evaluate the Efficacy and Safety of MK-5172 in Combination with Ribavirin (RBV) in Treatment-Naive (TN) Patients with Chronic Genotype 1 (GT 1) Hepatitis C Virus Infection" MK-5172-03
Merck Sharp & Dohme Corporation
6/1/12 → 6/1/13
Project: Research project
-
Prot# GX-US-174-0172: Prospective, Observational, Post-marketing Renal Safety Surveillance Registry in Patients with Chronic Hepatitis B (HBV) Infection with Decompensated Liver Disease Receiving Nucleotide/side Therapy While on the Orthotopic Liver Trans
PRA Health Sciences, Gilead Sciences, Inc.
3/19/12 → 3/19/18
Project: Research project
-
Prot# VX11-222-106: A Multicenter, Randomized, Double-blind, Placebo- Controlled, Phase 2b Study to Compare the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir, Peginterferon-Alfa-2, Ribavirin) to Triple Therapy (with VX-222-Placebo) in Subje
Parexel, Vertex Pharmaceuticals Incorporated
3/15/12 → 3/15/16
Project: Research project
-
Prot# VX11-950-116: An Open-Label, Phase 4 study of Telaprevir, Peginterferon Alfa-2a(Pegasys), and Ribavirin(Copegus) in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C Who Have Not
Parexel, Vertex Pharmaceuticals Incorporated
3/8/12 → 3/8/16
Project: Research project
-
Prot # VX11-950-114: A Phase 3b Study of 2 Treatment Durations of Telaprevir, Peg-IFN (Pegasys®), and Ribavirin (Copegus®) in Treatment-Naive and Prior Relapser Subjects With Genotype 1 Chronic Hepatitis C and IL28B CC Genotype
Parexel, Vertex Pharmaceuticals Incorporated
3/8/12 → 3/8/16
Project: Research project